Study Suggests States Could Save Up to $1.8 Billion Annually by Using Lower-Cost Biosimilars
A new analysis from the Pacific Research Institute suggests that state employee health plans could save up to $1.8 billion annually by increasing their use of biosimilar medicines, which are lower-cost alternatives to biologic drugs. The study highlights existing savings and emphasizes the potential for further cost reductions in states facing budget constraints.
Topics: biosimilars cost savings state budgets taxpayer impact